The Craziest Aurora Cannabis Statistic You'll Ever See | The Motley Fool

There's no denying that marijuana represents a long-term growth opportunity for investors. There are tens of billions of dollars in cannabis sales being conducted in the black market annually all over the world. If additional countries legalize weed and shuffle these consumers into legal channels, the sky could be the limit for those marijuana companies that are able to really stand out.Among investors, no pot stock is more popular than Aurora Cannabis (NYSE:ACB). In fact, according to online investing app Robinhood, which has 6 million members and is incredibly popular with millennials, Aurora was the most-held stock, period, earlier this year. Image source: Getty Images. Here's why Aurora Cannabis has been the most popular pot stock Aurora's popularity breaks down into three key areas. First, there's production. The company has 15 production facilities around the world that, if fully operational, could potentially yield close to 700,000 kilos of cannabis per year. With the exception of Canopy Growth and Flowr Corp., Aurora's peak output more than doubles up its competitors. With such robust output, the expectation is that Aurora will have little trouble securing long-term supply contracts in -- and outside of -- Canada. Secondly, there's the company's incredible international presence. Aurora Cannabis currently has a production, export, research, or partnership presence in 25 countries, including Canada. Only two other pot stocks have even reached the one-dozen country mark, including their home market of Canada. These external sales channels are expected to play a key role in the intermediate to long run, when dried flower becomes oversupplied and commoditized. Without these added sales channels, Aurora could succumb to domestic pricing pressures. Thirdly, investors appreciate the forecasted efficiency that Aurora's facilities bring to the table. The sheer size of Aurora's campuses should allow economies of scale to yield some of the lowest per-gram production costs in the industry. Meanwhile, yield on a per-gram basis at its largest grow farms should be somewhere in the range of 120 grams per square foot to 140 grams per square foot. Comparatively, most of its peers are liable to produce anywhere from 75 grams per square foot to 125 grams per square foot, making Aurora well above-average in the efficiency department. Image source: Getty Images. The craziest Aurora Cannabis statistic you'll ever see And yet, the most popular cannabis stock on the planet has been taken to the woodshed since hitting an all-time high eight months ago. Following the release of the company's fiscal first-quarter operating results, Aurora shares have now lost more than 75% from their closing high in March. But this isn't the scariest or craziest statistic you'll see with this company, as there are cannabis stocks that have performed far worse. The craziest thing about Aurora Cannabis is that, following its pummeling on Monday, Nov. 18, its goodwill of 3.17 billion Canadian dollars ($2.4 billion) is now larger than the company's market cap of $2.38 billion on the New York Stock Exchange. As a refresher, goodwill represents the "premium" paid above tangible assets that an acquiring company recognizes on its balance sheet when making a purchase. In theory, the purchaser will monetize any acquired patents and continue to develop the infrastructure of businesses acquired in an effort to recoup all of this premium, thereby eliminating goodwill from the balance sheet. But in practice, it doesn't always work this way. Aurora has made it no secret that acquisitions are a key component of its growth strategy. Since August 2016, Aurora has made more than a dozen acquisitions, with pretty much each and every buyout adding to its recognized goodwill. For instance, the MedReleaf purchase, which totaled CA$2.64 billion, led to CA$2 billion in recognized goodwill out of the company's current CA$3.17 billion. This goodwill currently accounts for 57% of total assets, which is a high-water mark among major pot companies -- and that's not an honor a business wants to have. Sometimes, the only effective way for a company to remove goodwill from its balance sheet is to admit that it grossly overpaid for an asset and take an impairment charge/writedown. What's truly terrifying in Aurora's case is that the value of its potential writedown (up to $2.4 billion) is larger than the company's current market cap of $2.38 billion. This is a big reason why Aurora Cannabis is no sure thing to rebound. Image source: Getty Images. Aurora's near-term prospects are dimming Of course, Aurora Cannabis' poor judgment when pricing acquisitions isn't entirely its fault. The company has had some assistance, with regulatory agency Health Canada and select provinces failing to help the marijuana industry in any meaningful way. For example, Health Canada entered 2019 with a mammoth pile of cultivation, processing, and sales license applications on its desk for review. Even with midyear changes being made to lessen the number of cultivation license applications to review, the agency is still likely numerous quarters away from making a dent in this backlog. Aphria, for instance, just received a green light to plant at its Aphria Diamond campus after a wait of between 18 to 21 months from its initial cultivation license application. Then there's Ontario, which is Canada's most populous province with 14.5 million people. To date, only around two dozen physical dispensaries have been opened, which means only one store for every 604,200 people in the province. This, along with a huge gap in per-gram price between legal and black-market weed, has made life very difficult early on for companies like Aurora Cannabis. To better align with current market conditions, Aurora announced in its first-quarter report that it'd be immediately stopping construction at Aurora Nordic 2 in Denmark (a 1 million-square-foot grow farm) and Aurora Sun in Alberta (a 1.62-million-square-foot cultivation facility) for the time being. Rather than yielding at least 350,000 kilos from these facilities, when at peak operating capacity, only six grow rooms spanning 238,000 square feet at Aurora Sun will come online in the meantime. This certainly saves Aurora cash and immediately reduces expenditures, but it also further exposes the company's already ugly balance sheet that's drowning in goodwill.  My suggestion is to not be tempted by Aurora's low-single-digit share price with the understanding that it's still carrying a toxic amount of potential future writedowns on its balance sheet.

Legal hemp, CBD stir more farmers to grow unfamiliar crop

(CNN Photo) × Legal hemp, CBD stir more farmers to grow unfamiliar crop (CNN Photo) CLAYTON TOWNSHIP, Mich. (AP) — Dave Crabill and two business partners started small for their first foray into farming hemp, growing two strains of the now-legal cousin of marijuana on an acre along a dirt road outside the industrial city of Flint. The endeavor wasn’t easy. Flooding from record rain stunted some plants. Crabill and others had to carefully walk the field and uproot 1,000 undesirable males, a third of the plants, to protect more valuable females. Some plants were stolen. And it’s still not clear whether they will make money from the effort, which Crabill likened to “planting $20 bills and hoping to harvest $50.” “That’s why we did the 1 acre,” said Crabill, who runs a small marketing company and is among more than 500 people who registered this year as hemp growers in Michigan, many hoping to capitalize on the growing demand for the extract CBD. “Something manageable. We can make mistakes and it won’t kill us. … We’re all going to be smarter next year.” The legalization of industrial hemp in the U.S. less than a year ago has sparked interest from both traditional farmers and newbies like Crabill. The early stages are proving tricky, but up for grabs is a lucrative market, one that could grow more than five-fold globally by 2025 — driven by demand for CBD. The compound, which doesn’t cause a high like that of marijuana, is hyped as a health product to reduce anxiety, treat pain and promote sleep. The U.S. is the biggest hemp-importing country, and even before the cannabis plant was fully legalized federally, some states ran pilot programs under the 2014 farm bill. Last month, the U.S. government finalized an interim national regulatory framework that is expected to pave the way for the crop’s widespread commercialization starting as early as 2020. In Michigan, farmers who participated in the state’s first growing season since World War II cover the gamut — including cannabis enthusiasts and large-scale operators who want to diversify beyond low-price commodities. For attorney Keith Hagen and his two farmer brothers, branching out past sugar beets, wheat and dry beans was primarily a financial decision. They founded Hempure Farm in Ubly and grew 340 acres (140 hectares) of hemp, the most statewide. “There’s not a lot of money being made in any crop right now. The margins are so small … and then you start piling on tariffs and those margins even get smaller,” Hagen said. “So when something new like hemp popped up, well they’ve got the agricultural expertise. It then just turned into a matter of learning as much as you can on how to do this.” Producing hemp, especially for CBD extraction, is labor-intensive. Obtaining high-quality seeds can be difficult and expensive. Weed control is an issue; little is known about safely or legally using pesticides. Before a crop is harvested, it’s tested for THC, the chemical in cannabis that causes a high. If the level is “hot,” above 0.3%, the plants must be destroyed. “It’s incredibly complicated,” Hagen said, pointing to “countless minefields” facing farmers, many of whom “will probably lose their shirt, for lack of a better term.” Vote Hemp says more than 30 states issued 17,800 licenses to farmers and researchers in the wake of hemp’s legalization, more than quintuple the 2018 figure. Of the half a million acres (202,350 hectares) covered, though, an estimated 295,000 (119,000 hectares) weren’t planted because of limited access to seedlings and clones, a lack of financing and a “huge number” of inexperienced growers, according to the nonprofit advocacy group. It estimates that about 50% to 60% of the planted acres, or 120,000 (48,560 hectares) to 144,000 (58,280 hectares), will be harvested, once crop failures, non-compliant plants and other factors are factored in. The U.S. Department of Agriculture’s newly issued interim rules to facilitate hemp production will provide much-needed guidance on testing, background checks and other issues. The industry also is closely tracking the U.S. Food and Drug Administration. Though products containing CBD are already in stores and sold online, the agency says CBD-infused foods, drinks and dietary supplements are illegal. It’s exploring ways that the compound might officially be allowed. “There is a bit of a medicinal market and there is a bit of an almost salon-type market,” said Hagen, who expects to produce about 1.5 million dried pounds (680,000 kilograms) of hemp this year for use in products such as lotions and oils. “The real launching point, though, is when the FDA allows CBD to be put into real consumable products. That’s where we’ll really see what this can do.” Ron Bates, director of the Michigan State University Extension’s Agriculture and Agribusiness Institute, said would-be growers should have contracts in place in advance. “You just don’t harvest this stuff and take it to the elevator and sell it,” he said. “The market infrastructure’s just not there yet.” For now, many states are playing catch-up. “This is really a learning year for everybody,” said Gina Alessandri, Michigan’s industrial hemp program director. “There still are a lot more questions than answers for many people.”

House Committee Bill To End Marijuana Prohibition |

The House Judiciary Committee passed a bill that would effectively make marijuana legal, the National Cannabis Industry Association (NCIA) announced in a press release on Wednesday (Nov. 20). The Marijuana Opportunity Reinvestment and Expungement (MORE) Act of 2019 passed by a count of 24-10. The legislation was introduced by Rep. Jerrold Nadler, (D-NY), and co-sponsored by more than 50 lawmakers. The bill would also introduce a 5 percent sales tax on cannabis sales in states where it’s legal, according to the bill, and establish an organization — the Cannabis Justice Office — to administer services for individuals most adversely impacted by the War on Drugs. Aaron Smith, executive director of the NCIA, said the landmark vote “marks a turning point for federal cannabis policy, and is truly a sign that prohibition’s days are numbered.”  He pointed to the “undeniable success” of state-run cannabis programs as one of the drivers that is fostering change. Under the MORE Act, marijuana would be removed from the Controlled Substances Act, federally legalizing cannabis across the country. In addition, past federal cannabis convictions would be required to be expunged.  A November Pew Research Center survey indicated that 75 percent of Americans think marijuana should be legal, an increase over the past 10 years. Adults who oppose legalization dropped from 52 percent in 2010 to 32 percent in 2019. According to the American Civil Liberties Union, marijuana arrests account for more than half of all U.S. drug arrests.  In passing the bill, lawmakers cited the “disproportionate impact” drug laws have had on minorities. The decriminalization of marijuana would tip the scales on that imbalance, CNBC reported. “The criminalization of marijuana has been a mistake,” Chairman Rep. Jerrold Nadler, D-N.Y., said during the markup of the bill, as reported by CNBC. “The racial disparity in marijuana enforcement laws only compounded this mistake with serious consequences, particularly for minority communities.” Federal legalization could also open more payment channels. Currently, regulations vary by state, making compliance a burden and creating a banking conundrum for a market forced to rely heavily on cash. ——————————– Latest Insights: Our data and analytics team has developed a number of creative methodologies and frameworks that measure and benchmark the innovation that’s reshaping the payments and commerce ecosystem. In the November 2019 Mobile Order-Ahead Report, PYMNTS talks with Dan Wheeler, Wahlburgers’ SVP, on how the QSR balances security and seamlessness to secure its recently launched WahlClub loyalty program. Recommended for you

New regulations for e-hailing and food delivery services

New regulations for food delivery scooters and e-hailing services may soon be implemented following an announcement from the City of Cape Town, that they will address the negative impacts these services have on traffic congestion and limited parking space in the CBD. As reported by IOL, ward councillor Dave Bryant said the motion was put forward in response to many queries by residents and local businesses within the CBD, who have raised concerns with regards to the challenges they face due to the many online delivery vehicles operating in the area. “One of the key challenges we are faced with is parking and stacking, in particular the scooters, and in some of these areas this causes congestion,” Bryant said. According to Bryant, the motion aims to not only “regulate the environment in the public interest”, but to also increase economic opportunities. The motion also aligns with other proposed amendments which involve e-hailing services across the city. Earlier this year, the City announced that its new by-laws would include a section that is tailored specifically to the e-hailing sector. E-hailing drivers who operate within the City’s jurisdiction will be required to clearly display a tag that identifies the vehicle as such, and drivers must have a valid operating license. Picture: Unsplash

UCLA awarded $3.5m grant to study pain relief and cannabis

© iStock/Thom_Morris The University of California, Los Angeles (UCLA), has been awarded a grant of $3.5m (~€3.16m) from the National Institutes of Health (NIH). The grant will go towards a five year study at UCLA, led by research director Ziva Cooper, that will study pain relief and cannabis – assessing the pain relieving effects of cannabis and cannabinoids. Studying cannabis and pain relief This grant will fund the first clinical study for the Cannabis Research Initiative, which was founded in 2017 as part of the Jane and Terry Semel Institute for Neuroscience and Human Behavior. Cooper joined the initiative as its first research director in January. Cooper, professor-in-residence of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA, said: “This is an ideal first project as it probes significant public health questions related to the potential medicinal and adverse effects of cannabis and cannabinoids, a central mission of the Initiative.” As part of the project, the research team will also be examining the addictive properties of cannabis, and will assess whether men and women experience the effects of the drug differently. Cooper said: “Evidence from animal studies show that females are more sensitive to the pain-relieving benefits of THC, the primary component of cannabis, however, they are also more sensitive to the negative effects.” At a time when rates of medicinal cannabis use are rapidly increasing among women, the study’s findings will help researchers better understand how men and women respond differently to both the potential therapeutic and negative effects of cannabis, Cooper said. The study will also explore whether hormones and endocannabinoids, the body’s own cannabinoid system, play a role in these differences. UCLA research initiative The Cannabis Research Initiative at UCLA (UCLA-CRI) is one of the first academic programmes in the world that is dedicated to the study of cannabis. Despite unprecedented access to cannabis, over half a century of research restrictions and limited funding have contributed to a lack of scientific knowledge about cannabis, particularly regarding the potential therapeutic use. The UCLA-CRI notes that its priority is to ‘study the therapeutic potential and health risks of cannabis on the body, brain, and mind’ as well as ‘to advance scientific understanding of the impacts of cannabis and hemp on body, brain, mind, and society.’

To Be Blunt: Cinema lacks accurate cannabis representation | Daily Trojan

Seanna Latiff | Daily Trojan In A24’s slick coming-of-age crime drama “Hot Summer Nights,” awkward and angsty teen Daniel (Timothée Chalamet) gets caught up with dealing weed in Cape Cod, Mass., in 1991. The film depicts the beginnings of his infatuation with cannabis and details the story of his fleeting business.In one scene, as Daniel tentatively hits a bong for the first time, experienced stoners observe him with careful yet blank concentration. When he takes the entire hit, one of them raises his hand gently, trying to communicate that the rookie inhaled way too much smoke. Daniel’s eyes widen with alarm as he abruptly stands upright, the camera immediately zooming in to catch his expression. A montage of cartoons and a shot of severe winds blowing back lines of trees in an orange haze follows an omniscient, premonitory voice narrating cannabis’ effects on the brain. When we return to Daniel, he’s already high as a kite, his eyes instantly drooping as he faints onto the floor, the stoner squad following his descent with their synchronized head tilts. Light, airy music plays in the background as the camera pans to the former cannabis virgin, his body language and facial features indicative of the euphoria he feels as he mumbles, “Oh my God.”  The first time I watched the scene, I believed it was absurd, comical and ridiculous. That is not what being high feels like, I thought. But, while dramatized, the depiction is honestly not too far off. Considering the fact that inhaling a large amount of smoke in one breath can make a person feel faint and that Chalamet’s character has asthma, it’s not too outlandish to think he could be so strongly affected by the bong hit.  Even more so, highs come in many different forms, especially with various consumption methods. Bong hits are particularly notorious for hitting really hard, really quickly — kind of like a train (but in a good way), a “whoosh” as I call it or, in Daniel’s case, like a wind blowing back some trees. But what I appreciate most about “Hot Summer Nights” is that it’s a film about weed that offers so much more than most because it avoids cannabis cliches and worn-out tropes. The best films and television shows, which arguably comprise the pinnacle of American popular culture, play with the idea of the subversive, the deviant and the taboo. Cannabis, along with other drugs, is at the top of the list, with entire movies dedicated to depicting its possession, sale, consumption and cultural impact.  Weed movies aren’t even that niche or specifically tailored to stoners but rather span genres like comedy, romance, crime and drama. When we look at the prevalence of cannabis depiction in film, it’s interesting to see what this portrayal looks like. While we’ve come a considerably long way from the bizarre inaccuracy of “Reefer Madness” —  a 1936 propaganda film that depicts weed as a gateway to committing acts of violence — and films like it, it’s not like we’ve exactly transcended far beyond stereotypical representations like the “criminal outcast,” “foolish philosopher” or the “lazy stoner” archetype.  After “Reefer Madness,” there was a significant 20-year gap between the next generation of stoner movies because of the Motion Picture Production Code, which restricted the showing of drug use on screen. The 1960s, the counterculture movement brought along with them the revival of stoner movies, which portrayed weed in a considerably different (yet still stereotypical) way, with the iconic duo of Cheech & Chong and their late ’70s comedy film, “Up in Smoke.”  In the ’90s, stoner comedy films saw an increase in representation, with Black men starring as protagonists in classics like “Half Baked” and “Friday.” However, this was short-lived, as the turn of the century brought a return to played-out, predictable comedies led by white men. Think “The Big Lebowski,” “Dude, Where’s My Car,” “Pineapple Express” and “Ted.” Let me step back for a second: Far be it from me to call for the end of all comedic depictions of stoners. Most stoner comedies are hilarious, and poking fun at stoners is too easy — what with the poor reaction time and tendency for paranoia.  I live for the iconic weed circle in “That ’70s Show,” the absurd weed dream scene in “Harold & Kumar go to White Castle,” the strange monologue about George and Martha Washington’s weed habits in “Dazed and Confused” and even the horrible giant cartoon joint in the god-awful “Mac & Devin Go to High School” as much as the next person.  But I am tired of the boring, repetitive portrayal of the white male protagonist stoner who ends up on a misadventurous journey with an equally unintelligent sidekick because they got high. I’m tired of the lack of representation of women, people of color, members of the LGBTQ community and people with disabilities in stoner narratives.  “It became depressingly clear how often films failed to represent the varying identities of smokers by bundling anyone who’s ever enjoyed a joint into the same patronising pile,” writes Charlie Graham-Dixon in Dazed, an English style magazine. Not only do stoner comedies exclude marginalized identities, they also portray cannabis in the same basic way, without taking into consideration the complexities of pot nor the various reasons why people use it. Where are the stoner dramas where cannabis is used to treat severe illnesses? What about telling the story of the War on Drugs and how Black and brown men are exponentially more likely to be imprisoned for posession than white men? What about stoner comedies led by women of color? What about more documentaries? Better yet, I want to see films treat cannabis like they now treat alcohol — like a normal thing any person would do. It can be a major plot point, but I’d rather see it depart from that mold. Pot no longer adds a risqué factor to films, and I desperately want Hollywood to do better. Films like “Dude,” a coming-of-age story about young women in high school and shows like “Broad City,” “High Maintenance” and “Atlanta” have started breaking the mold in unique ways. These shows treat weed seriously, tackling topics like mandatory drug tests and self-medication in ways that are poignant and funny. At the same time, we have shows like “Weeds” and “Disjointed,” which try to break molds but ultimately fail. While “Weeds” tells the story of a suburban mom who has to sell weed to survive, the show also makes it very clear she does not smoke and is forced into the cannabis business.  “Disjointed,” a show about a medical dispensary, takes strides for great representation through characters like Travis, who is business-driven, rational and occasionally smokes weed, and Carter, an Iraq veteran and Muslim who uses cannabis to combat his recurring PTSD. But it falls into annoying stereotypes with the portrayal of the absurd, stupid duo Dank and Dabby who (spoiler alert) realize they used to be academic geniuses when they get stuck on a roof deprived of cannabis for many hours. While we have made leaps over the past several decades, I would venture to say we’re not too far removed from the likes of “Reefer Madness.” Our modern stereotypes are seemingly better and more accurate, but they’re still profoundly ignorant, dangerous and ridiculous.  Now, more than ever, we need nuanced cultural depictions of weed in television and film. Popular culture drives change, and as legalization efforts sweep across the country, we need more accurate, touching films than stoner comedies can offer. Cannabis has more stories to tell, if we let it. Natalie Oganesyan is a sophomore writing about weed culture and politics. She is also the Arts & Entertainment Editor at the Daily Trojan. Her column, “To be Blunt,” runs every other Thursday.

Gommes closing after 80 years

Tari JeffersManjimup-Bridgetown Times Thursday, 21 November 2019 3:48PM Gommes Shoes Manjimup team members Tanisha Kammann, Rita Woodland and Coralie Potter will serve the community until the business' doors close for good. Credit: Tari Jeffers An historic fixture of Manjimup’s business community will close its doors in the near future after about 80 years of operation. Gommes Shoes is due to shut-up shop sometime soon and owner Les Holmes said it was disappointing, especially considering the Gommes brand had started in the town. “It was started by Eric Gomme, his son Laurie ran this and another four or five shops for 40-odd years,” Mr Holmes said. “He sold them to me and he still owns the building.” Mr Holmes said Mr Gomme was a fair landlord and the rent was not the reason the store was closing. “I have had to close six stores in the last two years, which is a sign of the times. Things like online shopping, payroll tax, cheaper well-advertised products and a weak economy have taken their toll,” Mr Holmes said. “I still have five Gommes stores throughout WA.” Mr Holmes thanked the community for its support and thanked and apologised to the loyal Manjimup staff who did their best. “If I could keep the store open, I would, but in the last four years there has been a very significant decline in turnover,” he said. In the 15 years Mr Holmes has owned the business, he said trends had not changed too much, they just circled back around. The business will stay open as long as there are shoes to sell. “I’m not sure when we’re closing,” he said. “There has been an extremely strong response to the closing-down sale.” Mr Holmes thanked the Manjimup Gommes team, including store manager Rita Woodland, who had been with the shop for many years. Sign up for our emails From around the site

Khiron Director and 55th President of Mexico, Vicente Fox to Present Keynote at UK Cannabis Investor Conference

TORONTO, Nov. 21, 2019 /PRNewswire/ -  Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Company Director and 55th President of Mexico, Vicente Fox, will present a keynote address at the Bryan, Garnier & Co Cannabis Conference, taking place on Thursday, November 28, 2019 in London, UK.Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)MoreHosted at The May Fair, the conference will bring together global leaders in the cannabis sector, with presentations and panel discussions on the future of medical cannabis in Europe and the developing market for recreational and wellness cannabis brands.Pres. Fox will present a keynote address at the conference, discussing the industry view from Latin America, the market opportunity for cannabis in Europe, and Khiron's focused strategy in these markets. Tejinder Virk, President, Khiron Europe, and Franziska Katterbach, Chief Legal Officer, Khiron Europe, will also present at the conference and will be available for one-on-one meetings which can be scheduled at investors@khiron.caAbout Khiron Life Sciences Corp. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. About Bryan, Garnier & CoBryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo, Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange. To register, please visit the conference webpage, journalists are welcome: continuesCautionary NotesForward-Looking StatementsThis press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.United States DisclaimerThis news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is availableNeither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.Further information in respect of the Company can be found at original content to download multimedia:

Germany's Finest Watchmaker Launches Debut Boutique In Sydney

German watchmaker A. Lange & Söhne can now officially call Australia its home away from home, with the opening of a first standalone boutique store in Sydney next month. Taking up residence in Martin Place, the company’s latest store will offer watch aficionados 164 square metres of retail space, set over three split-levels – plenty to peruse over the latest collections. Those aficionados are enticed in thanks to a large glass frontage, but the high-rollers can get an exclusive view of the entire store from a VIP lounge. The design of the store itself takes inspiration from the company’s expertly crafted timepieces, with steel and natural stone materials both being used, as well as a complementary shade of grey that matches the German silver used in every one of its watch movements. If you’re someone who knows their chronographs from their complications, you’ll be wise to pay a visit to Lange’s new boutique, as you’ll be able to gaze over some of the company’s finest and most intricate models, including the Tourbograph Perpetual ‘Pour le Mérite’, limited to just 50 pieces and the Triple Split, the world’s first mechanical split-seconds chronograph that allows multi-hour comparative time measurements. Advertisement Speaking of the new boutique, which will arrive as one of Lange’s largest worldwide, CEO Wilhelm Schmid said: “The number of knowledgeable watch enthusiasts and collectors in Australia is continuously growing, as is the demand for our timepieces. This is why Sydney is among the first sites where we implemented our new store design.” If you fancy taking a look over A. Lange & Söhne’s latest collections, you will be able to find the new boutique at 14 Martin Place in Sydney’s CBD. Read Next: